Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the use of single agent vs. doublet chemotherapy in elderly patients.
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from initial scan to choice of treatment.
Dr. Gerard Silvestri, Medical University of South Carolina, defines pulmonary function testing, and describes how lung cancer surgeons use them.
Dr. Gerard Silvestri, Medical University of South Carolina, discusses the use of PET scans in lung cancer workup.
Dr. Gerard Silvestri, Medical University of South Carolina, describes several procedures used to obtain biopsy tissue in order to diagnose lung cancer.
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
Dr. Ross Camidge talks about a clinical trial that will test to see if the drug tesevatinib will work to kill cancer that has progressed in the brains of EGFR-mutant lung cancer patients. The trial is scheduled to begin in late 2015 or early 2016.
On this Thanksgiving Day, we salute lung cancer patient Jason Karg and his wife Kristyl for reminding us of the important things in life. November is Lung Cancer Awareness Month. What are you grateful for?
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.
Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.
Well, here we are, barring any last minute complications my wife should start the TAK-788 trial next week. She has already had her main blood work and...
One year ago I had a CT scan due to some symptoms. No tumor or other abnormality was found. Last week I had a CT for a kidney stone. The radiologist...
My husband has nocturia - bad. Since his pneumonectomy (T3 N1 M0) In October 2014 he has been up every two to three hours to pee. He has not had a...
Hi, my mom has EGFR mutation (Exon21). I would like to find an oncologist in Dana Farber or Sloan Kettering Institution for 2nd opinion. Can anybody...
Dx 11/2016. + for exon 19 deletion, Rx. with Tarceva for 18 months. Tolerated well. Now on Tagrisso, not sure how well I'm tolerating as it's only...
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
[powerpress]
EGFR T790M is a point mutation in the EGFR gene that is associated with resistance to epidermal growth factor receptor (EGFR) kinase inhibitors like erlotinib and gefitinib. Since its initial discovery in 2005, the T790M mutation has been the subject of much research aiming to better understand drug resistance in non-small cell lung cancer (NSCLC). However, the role of T790M as a biomarker for the clinical care of lung cancer patients over the same time period has been less clear.
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
[powerpress]
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
[powerpress]
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.
[powerpress]
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.
[powerpress]
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.
[powerpress]
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.
[powerpress]
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.
[powerpress]
Every year, many of the most important developments in cancer care are presented at ASCO. This year, we've got what I think is a very important year in lung cancer, with several practice-changing results/.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.